Covishield and Covaxin vaccine: The world's largest nationwide covid vaccination campaign in India is starting today. Prime Minister Narendra Modi will launch it shortly through video conferencing. During this time Prime Minister Modi will address the nation. The country is currently allowed limited use of two Kovid vaccines in emergency situations. 'Kovishield' and 'Kovaxin' are the result of nearly nine months of hard work by scientists. Let us tell you the complete success story of 'Kovishield' and 'Kovaxin'.
Covshield covid vaccine
It was developed by Oxford University and the British-Swedish company AstraZeneca, after studying the format of adenoviruses that infected chimpanzees.
The first vaccine, whose scientific research on Phase III clinical trials was published, has also been approved for emergency use in Britain, Argentina, and Mexico.
Serum Institute of India mobilized in construction, possible to keep at two to eight degree Celsius temperature for at least six months, found 60 to 70 percent effective in the trial.
The Serum Institute, which is providing the vaccine to the Government of India at the rate of Rs 200 per dose, fixed the price of one dose for private establishments at Rs 1000.
The journey from being made to the vaccination center
April 2020: Oxford University began the process of assessing the impact of covishields on one thousand healthy adults aged 18 to 55 in the UK.
20 July 2020: The first round of testing is completed, with scientists talking about Kovishield being able to produce safe and strong resistance.
03 August 2020: DGCI allows Serum Institute of India to begin the second and third round clinical trial of Kovishield.
06 September 2020: AstraZenka halts the trial globally after a problem with one of the participants involved in the trial resumed in October.
08 December 2020: Oxford University and AstraZeneca present results of Phase III trial, 70% effective vaccine when given two doses.
14 December 2020: Serum Institute seeks approval for emergency use in India.
03 January 2021: DGCI permits limited use in emergency situations.
13 January 2021: Serum Institute dispatches the first batch of 54.72 lakh doses to 13 cities.
Dry run success
02 January 2021: First nationwide dry-run of vaccination in 74 districts.
08 January 2021: The second dry-run was successfully carried out in 737 districts.
Kovaxin is an indigenous biotech vaccine developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology.
The vaccine can be stored for at least one week at normal temperature.
No side effects were seen in human trials.
At two doses at a three-week interval, the viral proteins in the vaccine enable the immune system to fight infection.
Priced at Rs 295 per dose, the company has decided to give 16.5 lakh free of cost to the Indian government, out of a total of 55 lakh doses.
The journey from being made to reach the vaccination center
-30 June 2020: The Drug Controller General of India (DGCI) approved human trials of the first indigenous vaccine vaccine.
-July 2020: Human trials of covaxine started in institutes like AIIMS (Delhi-Patna) and PGIMS (Rohtak).
-23 October 2020: Bharat Biotech claims to be completely safe in the first-second round of covicin trials.
-16 November 2020: The company begins a third round of trials, also offering vaccines and technology transfers to Brazil.
-07 December 2020: Bharat Biotech seeks approval for the emergency use of covaxine.
-03 January 2021: DGCI permits limited use in emergency situations.
-13 January 2021: The first consignment of covaccine was supplied to 11 Indian cities.
Covaxin is a two-dose vaccine, ie it produces immunity against coronavirus infection after both doses. 0.5ml vaccine will be given in each dose and there will be an interval of four weeks for both doses. The vaccine will begin to show effect 14 days after both doses are given. The vaccine has been approved for emergency use in India and will only be given to people over 18 years of age.